SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy

This study is improving the accuracy of radiation dosimetry — measuring exactly how much radiation a patient receives and where it goes in the body — during treatment with 177Lu-PSMA-617 (Pluvicto), a radioactive drug used for metastatic castration-resistant prostate cancer. Researchers will use a specialized imaging technique (SPECT/CT) to track the drug's distribution more precisely. **You may be eligible if...** - You are male and 18 years or older - You have been scheduled to receive 177Lu-PSMA-617 (Pluvicto) treatment for metastatic castration-resistant prostate cancer - You are clinically stable as determined by your nuclear medicine doctor - You are willing and able to give informed consent **You may NOT be eligible if...** - You are unable to lie flat for the duration of the imaging scans Talk to your doctor to see if this trial is right for you.